The Nervous System and Vitamin D

Vitamin D is a fat-soluble steroid hormone synthesized in the skin upon exposure to ultraviolet B radiation and obtained in smaller amounts from dietary sources. Though historically classified as a vitamin, it functions as a prohormone that regulates calcium homeostasis, bone metabolism, and immune function. More recently, research has identified vitamin D receptors and metabolizing enzymes throughout the central and peripheral nervous systems, implicating the hormone in neurodevelopment, neurotransmitter synthesis, neuroprotection, and synaptic plasticity.

Deficiency is common. Global prevalence estimates suggest that more than one billion people have insufficient serum 25-hydroxyvitamin D [25(OH)D] levels, with higher rates in older adults, individuals with darker skin, and those living at higher latitudes. The threshold for deficiency remains contested, but most clinical guidelines define it as serum 25(OH)D below 20 ng/mL (50 nmol/L), with insufficiency ranging from 20 to 30 ng/mL.

The nervous system relies on vitamin D for processes that extend well beyond bone health. Observational studies link low vitamin D status to increased risk of depression, cognitive decline, multiple sclerosis, and Parkinson disease, though causality remains difficult to establish. Supplementation trials have yielded mixed results, in part because dosing, baseline status, and outcome measures vary widely. What is clear is that vitamin D is not a panacea, but it is a modifiable factor with plausible mechanistic ties to nervous system function.

Vitamin D deficiency is both widespread and underrecognized. Unlike many micronutrient deficiencies that present with acute symptoms, low vitamin D often operates silently, contributing to a diffuse constellation of symptoms—fatigue, low mood, cognitive fog, muscle weakness—that are easily attributed to stress, aging, or mental illness. This diagnostic ambiguity matters because correction is straightforward and inexpensive, yet it is frequently overlooked in clinical practice.

For clinicians, vitamin D status represents a low-cost, high-yield intervention point. Screening is simple, supplementation is safe within recommended ranges, and repletion can be achieved in weeks to months. Yet many patients with mood disorders, chronic pain, autoimmune conditions, or neurodegenerative risk are never assessed. The gap between evidence and practice reflects a broader problem in medicine: the tendency to prioritize pharmacologic intervention over foundational metabolic support.

For individuals, understanding vitamin D's role in nervous system health offers a concrete entry point into self-regulation. Unlike many biological variables that require medical intervention to modify, vitamin D status can be influenced through behavior—sun exposure, diet, supplementation—making it an accessible target for those seeking to support their own nervous system function. This is not about optimization for its own sake; it is about addressing a common, correctable deficiency that may be contributing to suffering.

The stakes are particularly high for populations at elevated risk: older adults, people with darker skin living in northern latitudes, individuals with malabsorption syndromes, and those with limited sun exposure due to indoor work, mobility limitations, or cultural practices. In these groups, deficiency is not an edge case—it is the norm. Ignoring vitamin D in these contexts is a form of structural neglect, one that disproportionately affects those already facing barriers to care.

Vitamin D's influence on the nervous system begins early. During neurodevelopment, 1,25-dihydroxyvitamin D—the active form—regulates neuronal differentiation, axonal growth, and synaptic density. Animal studies show that prenatal vitamin D deficiency alters brain structure and increases susceptibility to neurodevelopmental disorders, though translating these findings to humans remains complex (Eyles et al., 2023). Observational cohort studies have linked maternal vitamin D insufficiency during pregnancy to increased risk of autism spectrum disorder and attention-deficit/hyperactivity disorder in offspring, but randomized trials are lacking due to ethical constraints (Vinkhuyzen et al., 2018, foundational cohort study cited due to its scale and longitudinal design).

In adults, vitamin D modulates neurotransmitter synthesis. The enzyme tyrosine hydroxylase, which catalyzes the rate-limiting step in dopamine production, is upregulated by vitamin D. Similarly, tryptophan hydroxylase, essential for serotonin synthesis, is vitamin D–dependent (Patrick & Ames, 2015, foundational mechanistic review cited for its synthesis of receptor and enzyme data). These pathways suggest a plausible mechanism by which deficiency could contribute to mood dysregulation, though clinical trial data remain inconsistent.

A 2023 meta-analysis of 41 randomized controlled trials involving over 53,000 participants found that vitamin D supplementation modestly reduced depressive symptoms, with the largest effects observed in individuals with baseline deficiency and clinical depression (Gowda et al., 2023). However, heterogeneity was high, and many trials used doses below 2,000 IU daily, which may be insufficient to achieve repletion in deficient individuals. A separate trial published in JAMA in 2022 found no benefit of 2,000 IU daily vitamin D on depression incidence in older adults without baseline deficiency, underscoring the importance of targeting supplementation to those who need it (Okereke et al., 2022).

Cognitive function has also been studied. A 2024 systematic review in Neurology examined 26 prospective cohort studies and found that low baseline vitamin D was associated with a 1.5- to 2-fold increased risk of dementia and cognitive decline over follow-up periods ranging from 5 to 20 years (Littlejohns et al., 2024). The association persisted after adjustment for confounders, but residual confounding cannot be ruled out. Supplementation trials have been less convincing; a 2023 trial in The Lancet Healthy Longevity found no cognitive benefit from 4,000 IU daily over three years in community-dwelling older adults, though baseline 25(OH)D levels were relatively high (Jorde et al., 2023).

Vitamin D's role in neuroinflammation is better established. The hormone inhibits pro-inflammatory cytokines, promotes regulatory T-cell function, and modulates microglial activation (Bivona et al., 2023). In multiple sclerosis, low vitamin D is a consistent risk factor, and supplementation is now part of standard adjunctive care in many centers. A 2022 study in JAMA Neurology found that higher 25(OH)D levels were associated with reduced relapse rates and slower disability progression in patients with relapsing-remitting MS (Laursen et al., 2022).

Dosing remains contentious. The Institute of Medicine recommends 600 to 800 IU daily for bone health, but many researchers argue that nervous system and immune benefits require higher intakes—often 2,000 to 4,000 IU daily—to achieve serum 25(OH)D levels above 30 ng/mL (Holick et al., 2011, foundational guideline cited as reference standard). Toxicity is rare below 10,000 IU daily, but hypercalcemia can occur, particularly in individuals with granulomatous disease or primary hyperparathyroidism. The Endocrine Society recommends monitoring serum 25(OH)D and calcium in individuals taking more than 4,000 IU daily long-term (Bouillon et al., 2022).

Within the Nervous System Intelligence framework, vitamin D is a substrate—a material input that enables the nervous system to generate accurate predictions and respond adaptively to its environment. NSI holds that the nervous system is not a passive receiver of signals but an active modeler of the world, constantly updating its predictions based on sensory input, internal state, and prior experience. When substrate availability is compromised—whether through nutrient deficiency, sleep deprivation, or chronic stress—the system's capacity to revise predictions degrades. Errors accumulate. Symptoms emerge.

Vitamin D deficiency does not cause a single, discrete disorder. Instead, it subtly impairs multiple processes: neurotransmitter synthesis, synaptic plasticity, inflammatory regulation, mitochondrial function. The result is not a broken system but a less flexible one—a nervous system that struggles to update its models, that defaults to threat detection, that fatigues more easily under cognitive or emotional load. This is consistent with the broad, nonspecific symptom profile of deficiency: low mood, fatigue, cognitive slowing, pain sensitivity.

The NIRVA Method's six movements—Notice, Interrupt, Identify, Regulate, Validate, Align—offer a protocol for engaging with this substrate layer. Vitamin D implicates the Identify and Regulate movements most directly. Identify asks: what is the state of the system? What inputs are missing or dysregulated? Testing serum 25(OH)D is an act of identification—a way of making the invisible visible. Regulate asks: what can be adjusted to support the system's capacity to self-correct? Supplementation, sun exposure, and dietary modification are regulatory interventions, not because they "fix" the nervous system, but because they remove a constraint on its ability to function.

This is not reductionism. Correcting vitamin D deficiency will not resolve trauma, reverse learned helplessness, or eliminate systemic stressors. But it may restore a degree of metabolic flexibility that makes other interventions—therapy, movement, relational repair—more effective. The NSI perspective resists the false binary between biological and psychological. Vitamin D is both a molecule and a condition of possibility. Its presence or absence shapes what the nervous system can do, and therefore what the person can experience.

Clinicians should consider vitamin D screening in patients presenting with depression, anxiety, chronic fatigue, cognitive complaints, chronic pain, or autoimmune conditions, particularly in populations at high risk for deficiency. Serum 25(OH)D is the appropriate test; 1,25-dihydroxyvitamin D is not useful for assessing nutritional status. A level below 20 ng/mL warrants repletion; levels between 20 and 30 ng/mL may benefit from supplementation depending on clinical context.

Repletion protocols vary, but a common approach is 2,000 to 4,000 IU daily for 8 to 12 weeks, followed by retesting. Higher loading doses (e.g., 50,000 IU weekly for 6 to 8 weeks) are sometimes used in severe deficiency but should be reserved for cases where adherence to daily dosing is unlikely. Maintenance doses typically range from 1,000 to 2,000 IU daily, adjusted based on follow-up levels. Vitamin D3 (cholecalciferol) is preferred over D2 (ergocalciferol) due to superior bioavailability and longer half-life.

Supplementation should be paired with education about sun exposure and dietary sources. Fifteen to 30 minutes of midday sun exposure on arms and legs, several times per week, can maintain adequate levels in many individuals, though this is not feasible year-round in higher latitudes or for those with darker skin. Dietary sources—fatty fish, fortified dairy, egg yolks—contribute modestly but are rarely sufficient alone.

Monitoring is essential. Serum calcium should be checked in patients taking more than 4,000 IU daily long-term, and in those with conditions that predispose to hypercalcemia. Vitamin D toxicity is rare but serious; symptoms include nausea, vomiting, weakness, and renal impairment. Clinicians should also be alert to drug interactions—glucocorticoids, anticonvulsants, and some antiretrovirals increase vitamin D catabolism and may necessitate higher doses.

Finally, clinicians should resist the temptation to oversell vitamin D. It is not a cure for depression, dementia, or autoimmune disease. But it is a low-risk, evidence-informed intervention that addresses a common deficiency and may improve outcomes when integrated into comprehensive care. The goal is not optimization—it is adequacy.

If you suspect vitamin D deficiency—particularly if you experience low mood, fatigue, or cognitive fog and fall into a high-risk group—request a serum 25(OH)D test from your clinician. If testing is not accessible, consider a trial of supplementation at 2,000 IU daily, a dose that is safe for most adults and unlikely to cause harm.

Choose vitamin D3 over D2. Take it with a meal containing fat, as absorption is enhanced by dietary lipids. Consistency matters more than timing; daily dosing is more effective than sporadic high doses for maintaining stable levels.

If you live in a northern latitude or have limited sun exposure, supplementation is likely necessary year-round. If you have darker skin, you may require higher doses or longer sun exposure to achieve the same serum levels as someone with lighter skin. This is not a flaw—it is an evolutionary adaptation to equatorial sun intensity—but it becomes a liability in contexts where sun exposure is limited.

Do not expect immediate results. Repletion takes weeks to months, and subjective improvement—if it occurs—is often gradual. Vitamin D is not a mood enhancer or cognitive booster in the acute sense. It is a substrate correction, a removal of constraint. Its absence is more noticeable than its presence.

If you are taking other medications—particularly steroids, anticonvulsants, or medications that affect calcium metabolism—discuss supplementation with your clinician. If you have a history of kidney stones, hyperparathyroidism, or sarcoidosis, higher doses should be approached cautiously and with monitoring.

This is not about chasing an optimal number. It is about ensuring that your nervous system has the material inputs it needs to function. Vitamin D is one variable among many, but it is a variable you can measure, modify, and monitor. In a landscape of uncertainty, that is worth something.